18889881171
Kalkine 0
countryflagUS
Logi

AAPL 189.1 -6.9344% MSFT 361.17 -3.2001% NVDA 93.9716 -7.69% GOOGL 147.225 -2.3189% GOOG 149.2 -2.2473% AMZN 173.59 -2.7016% META 506.8 -4.6687% AVGO 148.55 -3.5452% LLY 738.02 -6.472% TSLA 239.865 -10.257% TSM 146.085 -7.1769% V 316.3 -6.8034% JPM 211.125 -7.1121% UNH 529.505 -2.0234% NVO 62.66 -6.617% WMT 83.2 -4.6528% LVMUY 114.68 -4.497% XOM 105.06 -6.5552% LVMHF 575.0 -4.485% MA 496.24 -6.4669%
AAPL 189.1 -6.9344% MSFT 361.17 -3.2001% NVDA 93.9716 -7.69% GOOGL 147.225 -2.3189% GOOG 149.2 -2.2473% AMZN 173.59 -2.7016% META 506.8 -4.6687% AVGO 148.55 -3.5452% LLY 738.02 -6.472% TSLA 239.865 -10.257% TSM 146.085 -7.1769% V 316.3 -6.8034% JPM 211.125 -7.1121% UNH 529.505 -2.0234% NVO 62.66 -6.617% WMT 83.2 -4.6528% LVMUY 114.68 -4.497% XOM 105.06 -6.5552% LVMHF 575.0 -4.485% MA 496.24 -6.4669%

Intracellular Th

Healthcare US ITCI

131.87USD
-(-%)

Last update at 2025-04-02T13:30:00Z

Day Range

131.87131.87
LowHigh

52 Week Range

45.5084.89
LowHigh

Fundamentals

  • Previous Close 131.87
  • Market Cap6927.83M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-131.41500M
  • Revenue TTM513.93M
  • Revenue Per Share TTM5.34
  • Gross Profit TTM 95.16M
  • Diluted EPS TTM-1.16

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

2018-12-312019-12-312020-12-312021-12-312022-12-31-250M-200M-150M-100M-50M0M50M100M150M200M
Total Revenue
Net Income

Balancesheet

2019-12-312020-12-312021-12-312022-12-312023-12-310M100M200M300M400M500M600M700M
Total Assets
Total Liabilities

Change in Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-40M-30M-20M-10M0M10M20M30M40M50M

Total Operating Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-280M-260M-240M-220M-200M-180M-160M-140M-120M-100M

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -256.25000M -284.12003M -226.99215M -147.72058M -155.12581M
Minority interest - - - - -
Net income -256.25600M -284.12567M -227.00566M -147.72218M -155.12741M
Selling general administrative 358.78M 272.61M 186.36M 64.95M 30.10M
Selling and marketing expenses - - - - -
Gross profit 228.69M 73.67M 20.64M 0.06M -132.16691M
Reconciled depreciation 0.66M 0.53M 0.53M 0.48M 0.37M
Ebit -264.28200M -286.22148M -231.75575M -154.48897M -162.63544M
Ebitda -263.62600M -285.68813M -231.22763M -154.01185M -162.26677M
Depreciation and amortization 0.66M 0.53M 0.53M 0.48M 0.37M
Non operating income net other 7.38M 1.57M 4.24M 6.29M 7.14M
Operating income -263.62600M -285.68813M -231.22763M -154.01185M -162.26677M
Other operating expenses 512.76M 367.40M 253.76M 154.07M 162.27M
Interest expense 7.38M 2.10M 4.76M 6.77M 0.00000M
Tax provision 0.00600M 0.00563M 0.01M 0.00160M 0.00160M
Interest income 7.38M 1.57M 4.24M 6.29M 7.14M
Net interest income 7.38M 1.57M 4.24M 6.29M 7.14M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00600M 0.00563M 0.01M 0.00160M 0.00160M
Total revenue 249.13M 81.71M 22.53M 0.06M 0.00000M
Total operating expenses 492.31M 359.36M 251.86M 154.07M 162.27M
Cost of revenue 20.44M 8.03M 1.90M 89.12M 132.17M
Total other income expense net 7.38M 1.57M 4.24M 6.29M 7.14M
Discontinued operations - - - - -
Net income from continuing ops -256.25600M -284.12567M -227.00566M -147.72218M -155.12741M
Net income applicable to common shares -256.25600M -284.12567M -227.00566M -147.72218M -155.12741M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 728.29M 754.78M 489.92M 717.31M 251.19M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 42.44M 45.19M 26.84M 15.64M 6.31M
Total liab 136.87M 98.71M 72.03M 60.45M 56.18M
Total stockholder equity 591.42M 656.07M 417.89M 656.86M 195.01M
Deferred long term liab - - - - -
Other current liab 108.48M 68.27M 37.93M 25.81M 25.61M
Common stock 0.01000M 0.00900M 0.00819M 0.00805M 0.00555M
Capital stock 0.01000M 0.00900M 0.00819M 0.00805M 0.00555M
Retained earnings -1617.16000M -1477.48600M -1221.22970M -937.10403M -710.09837M
Other liab - - - - -
Good will - - - - -
Other assets - 0.09M 0.09M 0.09M 0.35M
Cash 147.77M 148.62M 92.36M 60.05M 107.64M
Cash and equivalents - - - - -
Total current liabilities 123.55M 83.24M 53.36M 36.85M 36.22M
Current deferred revenue - - - - -
Net debt -130.82900M -128.57400M -66.95825M -30.90378M -84.49423M
Short term debt 3.61M 4.57M 6.73M 5.54M 3.19M
Short long term debt - - - - -
Short long term debt total 16.94M 20.04M 25.41M 29.14M 23.14M
Other stockholder equity 2208.47M 2137.74M 1639.48M 1593.48M 904.97M
Property plant equipment - 1.91M 22.56M 2.00M 2.26M
Total current assets 667.80M 737.96M 467.28M 690.90M 230.32M
Long term investments - - - - -
Net tangible assets - 656.07M 417.89M 656.86M 195.01M
Short term investments 350.17M 443.29M 319.97M 597.40M 116.37M
Net receivables 114.02M 75.19M 20.16M 10.76M 0.35M
Long term debt - - - - -
Inventory 11.65M 23.92M 7.95M 7.06M -
Accounts payable 11.45M 10.39M 8.69M 5.50M 7.43M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.10M -4.19000M -0.36365M 0.48M 0.13M
Additional paid in capital - - - - -
Common stock total equity - 0.00900M 0.00819M 0.00805M 0.00555M
Preferred stock total equity - - - - -
Retained earnings total equity - -1477.48600M -1221.22970M -937.10403M -710.09837M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 45.91M 0.09M 0.09M 0.09M 0.09M
Deferred long term asset charges - - - - -
Non current assets total 60.50M 16.82M 22.64M 26.41M 20.86M
Capital lease obligations 16.94M 20.04M 25.41M 29.14M 23.14M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -127.59500M 280.67M -480.02828M 178.14M 135.03M
Change to liabilities 12.39M 3.19M -1.72516M -3.20894M 22.17M
Total cashflows from investing activities -128.37300M 280.34M -480.29500M 177.44M 134.64M
Net borrowings - - - - -
Total cash from financing activities 455.16M 11.52M 664.18M 3.24M 0.69M
Change to operating activities 11.16M 0.74M -7.79679M 5.68M 11.63M
Net income -256.25600M -284.12567M -227.00566M -147.72218M -155.12741M
Change in cash 56.60M 32.32M -46.19092M 52.69M 17.16M
Begin period cash flow 93.77M 61.45M 107.64M 54.95M 37.79M
End period cash flow 150.37M 93.76M 61.45M 107.64M 54.95M
Total cash from operating activities -270.18600M -259.54348M -230.07285M -127.98324M -118.16911M
Issuance of capital stock 433.72M 0.00000M 652.71M 0.00000M 0.00000M
Depreciation 0.66M 0.53M 0.53M 0.48M 0.37M
Other cashflows from investing activities - - - 178.14M 135.03M
Dividends paid - - - - -
Change to inventory -15.97200M -0.89174M -7.05638M -7.05638M -7.05638M
Change to account receivables -55.03300M -9.39141M -10.76458M -10.76458M -10.76458M
Sale purchase of stock 455.16M 11.52M 664.18M 3.24M 0.69M
Other cashflows from financing activities 21.44M 11.52M 11.46M 3.24M 0.69M
Change to netincome 43.10M 30.40M 24.59M 21.25M 18.12M
Capital expenditures 0.78M 0.33M 0.27M 0.70M 0.39M
Change receivables -55.03300M -9.39141M -10.76458M - -
Cash flows other operating 0.48M -11.38303M -7.99483M 2.35M -2.75932M
Exchange rate changes - - - - -
Cash and cash equivalents changes 56.60M 32.32M -46.19092M 52.69M 17.16M
Change in working capital -58.13600M -6.35291M -27.27635M -0.58948M 19.94M
Stock based compensation 43.01M 34.30M 24.12M 20.79M 17.40M
Other non cash items 0.54M 0.18M 0.21M 0.19M -529.96771M
Free cash flow -270.96400M -259.86922M -230.33957M -128.68364M -118.56038M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ITCI
Intracellular Th		 - -% 131.87 - - 13.73 10.78 12.76 -37.1202
ZTS
Zoetis Inc		 -7.4395 4.66% 152.17 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -1.13 4.22% 25.64 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 141.81 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.395 2.60% 14.79 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Intracellular Th

430 East 29th Street, New York, NY, United States, 10016

Key Executives

Name Title Year Born
Dr. Sharon Mates Ph.D. Co-Founder, Chairman, CEO & Pres 1953
Mr. Lawrence J. Hineline CPA, CPA Sr. VP of Fin., CFO, Treasurer & Assistant Sec. 1956
Mr. Michael I. Halstead J.D. Exec. VP, Gen. Counsel & Sec. 1973
Dr. Suresh K. Durgam M.D. Exec. VP & Chief Medical Officer 1969
Mr. Mark Neumann EVP & Chief Commercial Officer 1963
Dr. Robert E. Davis Ph.D. Sr. VP & Chief Scientific Officer 1951
Mr. Juan Fernando Sanchez VP of Corp. Communications & Investor Relations 1971
Ms. Karen Patruno Sheehy Esq. Sr. VP & Chief Compliance Officer 1962
Dr. Michael Olchaskey Sr. VP & Head of Regulatory Affairs NA
Mr. John A. Bardi Sr. VP of Market Access, Policy & Gov. Affairs NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.